ZymoGenetics

Douglas Williams turned heads in July when Biogen revealed that its executive vice president leading research and development was leaving to found a biotechnology startup, and now Williams has emerged

Before they began their summer vacations, three biotechnology companies raised $62m in venture capital financing and three drug developers grossed $232m in initial public offerings. Venture capital in

Novo Nordisk AS is cutting its R&D losses in inflammatory disorders by exiting that disease area to focus more on treating and preventing diabetes and obesity. The move, announced Sept. 2, came when

Novo Nordisk is dropping all its R&D activities into inflammatory disorders following the discontinuation of its lead anti-inflammatory product, anti-IL-20 for the treatment of rheumatoid arthritis, w